Valuation models
price $170.68 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused138.27 – 239.65176.043% undervaluedDCF · Perpetuity growth · 10y163.01 – 274.75204.8017% undervaluedDCF · EBITDA exit · 5y159.96 – 175.45167.502% overvaluedDCF · EBITDA exit · 10y181.70 – 214.02197.0913% undervaluedP/E · peers139.25 – 418.20174.112% undervaluedP/E · own history110.74 – 159.20139.8122% overvaluedPEG—161.006% overvaluedEV/EBITDA · peers155.10 – 338.34203.0316% undervaluedEV/Revenue · peers125.89 – 279.48163.105% overvaluedEarnings power value59.68 – 99.4975.27127% overvaluedDividend discount61.14 – 206.4598.7573% overvaluedWall St. consensus target—175.002% belowCost of capital (WACC)—6.92%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
176.04
Gilead Sciences closed at $170.68 — undervalued by 3% vs model.
138.27the model's range239.65
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
75.27 – 204.80
Wall St. target
175.00 2% below
Below model, 1y
18 of 31 days
How it is valued
Valued asMature & stable
Low/slowing growth (~4% recent)High profitability (29% net margin)Pays dividendsHighly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.